Molecular hydrogen supplementation in mice ameliorates lipopolysaccharide-induced loss of interest.
Minori Koga, Mayumi Sato, Ryuichi Nakagawa, Shinichi Tokuno, Fumiho Asai, Yuri Maezawa, Masanori Nagamine, Aihide Yoshino, Hiroyuki Toda · PCN reports : psychiatry and clinical neurosciences · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In ICR mice with lipopolysaccharide-induced inflammation-related behavioral changes, however, the H₂ ‐LPS group showed a significant reduction (51.13 ± 6.777 times, p < 0.0001); thus, hydrogen supplementation did not reverse the LPS‐induced reduction (Figure 5d ). After 7 days of hydrogen jelly intake, no significant difference in body weight was observed between the hydrogen and air jelly mice groups (rmANOVA; Figure 3 ). These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how hydrogen-supplemented jelly intake affected the outcomes measured in ICR mice with lipopolysaccharide-induced inflammation-related behavioral changes. However, the H₂ ‐LPS group showed a significant reduction (51.13 ± 6.777 times, p < 0.0001); thus, hydrogen supplementation did not reverse the LPS‐induced reduction (Figure 5d ).
What the Researchers Studied
The researchers studied ICR mice with lipopolysaccharide-induced inflammation-related behavioral changes. The study used a preclinical animal experiment. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 7 days. However, the H₂ ‐LPS group showed a significant reduction (51.13 ± 6.777 times, p < 0.0001); thus, hydrogen supplementation did not reverse the LPS‐induced reduction (Figure 5d ). The authors concluded that hydrogen administration demonstrated a preventive effect against the LPS-induced loss of interest, suggesting a potential role in symptom prevention. The objective of this study was to evaluate the potential of hydrogen in preventing and treating psychiatric symptoms, particularly depressed mood and loss of interest, and to explore its underlying mechanisms.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was ICR mice with lipopolysaccharide-induced inflammation-related behavioral changes. The study used a preclinical animal experiment. The hydrogen delivery method was hydrogen-supplemented jelly intake. The reported treatment duration was 7 days.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.